Use of G-CSF for granulocyte transfusion therapy.
Patients with neutropenia, especially neutropenia following aggressive myeloablative therapy, are at high risk for developing infectious complications caused by bacteria and opportunistic fungi. Infections remain one of the leading causes of treatment failure in patients with cancer. Thus, new and innovative therapeutic strategies are needed for management of neutropenic patients with infection. Because neutrophils represent the first line of host defense, granulocyte transfusion therapy should be a logical therapeutic approach. Although such therapy has been employed sporadically for several decades, clinical benefit has been compromised by technical problems and low granulocyte yields resulting from inadequate donor stimulation. The discovery of granulocyte colony-stimulating factor (G-CSF) as a means to elevate blood neutrophil counts when administered to normal donors has rekindled interest in granulocyte transfusion therapy. Extensive experience has been gained worldwide with G-CSF in clinical practice, and adverse events have been minimal when G-CSF has been administered to patients or healthy persons in human trials. This review focuses on the use of G-CSF in granulocyte transfusion therapy, including technical considerations of granulocyte leukapheresis and storage, donor selection and stimulation, as well as treatment results and associated risks.
Hübel
K
K
Department of Medicine, University of Washington, Seattle 98195-7185, USA.
Dale
D C
DC
Engert
A
A
Liles
W C
WC
D001782:Blood Donors; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes / Q000637:transplantation*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D017708:Leukocyte Transfusion / Q000379:methods*; D009503:Neutropenia / Q000628:therapy*; D011994:Recombinant Proteins; D014019:Tissue Donors
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor